A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 1, Issue 1, 2006, Pages 46-51

  Nagai, Shinjiro ^a   Takenaka, Kazumasa ^a   Sonobe, Makoto ^a   Ogawa, Eiji ^a   Wada, Hiromi ^a   Tanaka, Fumihiro ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Immunohistochemistry; Lung cancer; MUC1; Prognosis

Indexed keywords

CA15 3 PROTEIN; EPITOPE; MONOCLONAL ANTIBODY; MUC1 MONOCLONAL ANTIBODY; MUCIN 1; TUMOR MARKER; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DNA; MUC1 PROTEIN, HUMAN; MUCIN; TUMOR ANTIGEN;

ADULT; AGED; CANCER CLASSIFICATION; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TUMOR DIFFERENTIATION; ARTICLE; BIOSYNTHESIS; CLASSIFICATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; LUNG RESECTION; LUNG TUMOR; METABOLISM; PATHOLOGY; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; SURVIVAL RATE;

AGED; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MUCINS; NEOPLASM STAGING; PNEUMONECTOMY; POSTOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 34247854880     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200601000-00010     Document Type: Review

References (40)

1. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 1990;265:15286-15293.
2. Lan MS, Batra SK, Qi WN, et al. Cloning and sequencing of a human pancreatic mucin cDNA. J Biol Chem 1990;265:15294-15299.
3. Ligtenberg MJ, Vos HL, Gennisen AM, et al. Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem 1990;265:5573-5578.
4. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-651.
5. Seregni E, Botti C, Rombardo C, et al. Pattern of mucin gene expression in normal and neoplastic lung tissues. Anticancer Res 1996;16:2209-2214.
6. Jarrard JA, Linnoila RI, Lee HR, et al. MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis. Cancer Res 1998;58:5582-5589.
7. Hilkens J, Lightenberg MJ, Vos HL, et al. Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci 1992;17:359-363.
8. Wesseling J, van der Valk SW, Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996;7:565-577.
9. Wesseling J, van der Valk SW, Vos HL, et al. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995;129:255-265.
10. Pandey P, Kharbanda S, Kufe D. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res 1995;55:4000-4003.
11. Yamamoto M, Bharti A, Li Y, et al. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and β-catenin in cell adhesion. J Biol Chem 1997;272:12492-12494.
12. Li Y, Ren J, Yu W, et al. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and β-catenin. J Biol Chem 2001;276:35239-35242.
13. Schroeder JA, Thompson MC, Gardner MM, et al. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001;276:13057-13064.
14. Schroeder JA, Masril AA, Adriance MC, et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004;23:5739-5747.
15. Agrawal B, Reddish MA, Longenecker BM, et al. In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol 1996;157:2089-2095.
16. Pecher G, Finn OJ. Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Proc Natl Acad Sci USA 1996;93:1699-1704.
17. Broadbeut R, Thynne G, McKenzie IFC. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 1997;100:2783-2792.
18. Kontani K, Taguchi O, Ozaki Y, et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med 2003;12:493-502.
19. Wreesmann VB, Sieczka EM, Socci ND, et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 2004;64:3780-3789.
20. Diaz LK, Wiley EL, Morrow M. Expression of epithelial mucins Muc1, Muc2, and Muc3 in ductal carcinoma in situ of the breast. Breast J 2001;7:40-45.
21. Shinozaki E, Adachi S, Shoda J, et al. Subcellular localization of MUC1 recognized by a monoclonal antibody MY.1E12 correlates with postsurgical prognosis in differentiated-type gastric carcinomas of stage II and III. Int J Oncol 2004;25:1257-1265.
22. Utsunomiya T, Yonezawa S, Sakamoto H, et al. Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. Clin Cancer Res 1998;4:2605-2614.
23. Hinoda Y, Ikematsu Y, Horinouchi M, et al. Increased expression of MUC1 in advanced pancreatic cancer. J Gastroenterol 2003;38:1162-1166.
24. Tamada S, Goto M, Nomoto M, et al. Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis. Pathol Int 2002;52:713-723.
25. Matsumura N, Yamamoto M, Aruga A, et al. Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer 2002;94:1770-1776.
26. Kawamoto T, Shoda J, Miyahara N, et al. Expression of MUC1 recognized by a monoclonal antibody MY.1E12 is a useful biomarker for tumor aggressiveness of carcinoma of the gallbladder. Clin Exp Metastasis 2004;21:353-362.
27. Feng H, Ghazizadeh M, Konishi H, et al. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol 2002;32:525-529.
28. Sivridis E, Giatromanolaki A, Koukourakis MI, et al. Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance. Histopathology 2002;40:92-100.
29. Kirschenbaum A, Itzkowitz SH, Wang JP, et al. MUC1 Expression in prostate carcinoma: correlation with grade and stage. Mol Urol 1999;3:163-168.
30. Baldus SE, Monig SP, Huxel S, et al. MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. Clin Cancer Res 2004;10:2790-2796.
31. Guddo F, Giatromanolaki A, Koukourakis MI, et al. MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 1998;51:667-671.
32. Tsutsumida H, Goto M, Kitajima S, et al. Combined status of MUC1 mucin and surfactant apoprotein A expression can predict the outcome of patients with small-size lung adenocarcinoma. Histopathology 2004;44:147-155.
33. Tanaka F, Ynanagihara K, Otake Y, et al. Surgery for non-small cell lung cancer: postoperative survival based on the revised tumor-nodemetastasis classification and its time trend. Eur J Cardiothorac Surg 2000;18:147-155.
34. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717.
35. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Tumours of the lung. In Travis WD (Ed), World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart . Lyon: IARC Press, 2004. Pp 9-124.
36. Guddo F, Giatromanolaki A, Patriarca C, et al. Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression. Anticancer Res 1998;18:1915-1920.
37. Awaya H, Takeshima Y, Yamasaki M, et al. Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol 2004;121:644-653.
38. Murray N, Butts A, Maksymiuk E, et al. A liposomal MUC1 vaccine for treatment of non-small cell lung cancer (NSCLC): updated survival results from patients with stage IIIB disease (Abstract 7037). J Clin Oncol 2006;23 (Suppl I):629s.
39. Velu T, Ramlau E, Quoix M, et al. A phase II study evaluating the clinical efficacy of TG4010 (MVA-MUC1-IL2) in association with chemotherapy in patients with non-small cell lung cancer (Abstract 7132). J Clin Oncol 2006;23 (Suppl I):653s.
40. Ogawa M, Umehara K, Yu WG, et al. A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for interleukin-12-induced tumor regression. Cancer Res 1999;59:1531-1538.